1|BACKGROUND Since 2004,the treatment landscape of metastatic prostate cancer(mPC)has significantly changed.When added to androgen deprivation therapy(ADT),many treatments demonstrated to improve overall survival(OS)o...1|BACKGROUND Since 2004,the treatment landscape of metastatic prostate cancer(mPC)has significantly changed.When added to androgen deprivation therapy(ADT),many treatments demonstrated to improve overall survival(OS)of mPC patients both in hormone-sensitive(mHSPC)[1]and castration-resistant(mCRPC)setting[2].With multiple available options,therapy selection and the optimal treatment sequence are currently crucial clinical challenges.展开更多
文摘1|BACKGROUND Since 2004,the treatment landscape of metastatic prostate cancer(mPC)has significantly changed.When added to androgen deprivation therapy(ADT),many treatments demonstrated to improve overall survival(OS)of mPC patients both in hormone-sensitive(mHSPC)[1]and castration-resistant(mCRPC)setting[2].With multiple available options,therapy selection and the optimal treatment sequence are currently crucial clinical challenges.
